A detailed history of Woodline Partners LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 306,458 shares of CPRX stock, worth $6.65 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
306,458
Previous 503,735 39.16%
Holding current value
$6.65 Million
Previous $7.8 Million 21.92%
% of portfolio
0.06%
Previous 0.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.19 - $21.35 $3 Million - $4.21 Million
-197,277 Reduced 39.16%
306,458 $6.09 Million
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $337 - $389
-23 Reduced -0.0%
503,735 $7.8 Million
Q1 2024

May 15, 2024

BUY
$13.18 - $17.11 $6.64 Million - $8.62 Million
503,758 New
503,758 $8.03 Million
Q2 2023

Aug 14, 2023

BUY
$11.5 - $18.08 $2.91 Million - $4.58 Million
253,325 New
253,325 $3.4 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.23B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.